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Abstract
Introduction: Carcinoma-associated fibroblasts (CAFs) play a pivotal role in cancer progression by contributing to
invasion, metastasis and angiogenesis. Solid tumors possess a unique microenvironment characterized by local
hypoxia, which induces gene expression changes and biological features leading to poor outcomes. Hypoxia
Inducible Factor 1 (HIF-1) is the main transcription factor that mediates the cell response to hypoxia through
different mechanisms that include the regulation of genes strongly associated with cancer aggressiveness. Among
the HIF-1 target genes, the G-protein estrogen receptor (GPER) exerts a stimulatory role in diverse types of cancer
cells and in CAFs.
Methods: We evaluated the regulation and function of the key angiogenic mediator vascular endothelial growth factor
(VEGF) in CAFs exposed to hypoxia. Gene expression studies, Western blotting analysis and immunofluorescence
experiments were performed in CAFs and breast cancer cells in the presence of cobalt chloride (CoCl2) or cultured
under low oxygen tension (2% O2), in order to analyze the involvement of the HIF-1a/GPER signaling in the biological
responses to hypoxia. We also explored the role of the HIF-1a/GPER transduction pathway in functional assays like tube
formation in human umbilical vein endothelial cells (HUVECs) and cell migration in CAFs.
Results: We first determined that hypoxia induces the expression of HIF-1a and GPER in CAFs, then we
ascertained that the HIF-1a/GPER signaling is involved in the regulation of VEGF expression in breast cancer cells
and in CAFs exposed to hypoxia. We also assessed by ChIP assay that HIF-1a and GPER are both recruited to the
VEGF promoter sequence and required for VEGF promoter stimulation upon hypoxic condition. As a biological
counterpart of these findings, conditioned medium from hypoxic CAFs promoted tube formation in HUVECs in a
HIF-1a/GPER dependent manner. The functional cooperation between HIF-1a and GPER in CAFs was also
evidenced in the hypoxia-induced cell migration, which involved a further target of the HIF-1a/GPER signaling like
connective tissue growth factor (CTGF).
Conclusions: The present results provide novel insight into the role elicited by the HIF-1a/GPER transduction
pathway in CAFs towards the hypoxia-dependent tumor angiogenesis. Our findings further extend the molecular
mechanisms through which the tumor microenvironment may contribute to cancer progression.
Introduction
The cooperative interactions among tumor cells and reac-
tive stroma strongly contribute to cancer development and
progression [1,2]. Cancer-associated fibroblasts (CAFs)
have been indicated as the main cellular component of the
tumor microenvironment involved in cancer initiation,
invasion and metastasis [3-5]. In breast malignancies,
CAFs exert a pivotal role in tumor progression and
resistance to therapeutics through multiple mechanisms,
including the stimulation of new blood vessels [6], mainly
generated by a hypoxic tumor microenvironment [7-9].
Indeed, mechanisms of cell sensing and adaptation to
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stressful environments are activated within the hypoxic
tumor mass, leading to the growth and aggressiveness of
malignant cells [10]. The transcription factor Hypoxia
Inducible Factor 1 (HIF-1) primarily mediates the cell
responses to a low oxygen tension playing a crucial role in
cancer development [11,12]. In particular, HIF-1 activates
a signaling transduction network which drives the adapta-
tion of tumor cells to hypoxic conditions towards a more
aggressive cancer phenotype [13]. HIF-1 is a heterodimeric
protein composed of the hypoxia-inducible a subunit and
the constitutively expressed b subunit [14]. HIF-1a and
HIF-1b dimerize upon exposure to hypoxia, generating a
complex which binds to the hypoxia-responsive elements
(HREs) located within the promoter region of target genes
[15]. In this regard, it has been shown that HIF-1 is a lead-
ing regulator of tumor angiogenesis following hypoxia, as
it regulates the expression of several pro-angiogenic
factors, like the vascular endothelial growth factor (VEGF-
A) [16-18]. Recently, we discovered a further HIF-1-regu-
lated gene, the G-protein estrogen receptor (GPER), which
contributes to the adaptation to a low oxygen environment
in breast cancer cells and in cardiomyocytes [19]. In
particular, we found that the cooperation between GPER
and HIF-1a upon exposure to hypoxia leads to the up-reg-
ulation of the Connective Tissue Growth Factor (CTGF)
[19], which is a target gene of both HIF-1a [19,20] and
GPER [21,22]. Surprisingly, we also assessed that in CAFs
derived from breast cancer malignancies GPER acts as a
transcription factor promoting the expression of genes
involved in cell proliferation and migration [23]. On the
basis of these data, GPER-mediated functions may be
included among the mechanisms driving the biological
responses to hypoxia within the tumor microenvironment.
Considering that hypoxia regulates HIF-1a-dependent
expression of both GPER and VEGF in different model
systems, in the present study we aimed to evaluate the
potential involvement of GPER in the expression and
function of VEGF in CAFs and breast cancer cells.
In this regard, we demonstrate that HIF-1a/GPER
signaling mediates the up-regulation of VEGF as well as
the endothelial tube formation, suggesting that this
transduction pathway may be involved in the intricate
stimulatory responses to hypoxia within the cancer
stroma. Our data may open new perspectives towards




Cobalt chloride (CoCl2) and the ROS scavenger N-acetyl-
L-cysteine (NAC) were purchased from Sigma-Aldrich
Srl (Milan, Italy). PD98059 (PD) was obtained from
Calbiochem (Milan, Italy). Human CTGF was purchased
from MBL International Corporation, distributed by
Eppendorf, (Milan, Italy). Human VEGF was purchased
from Peprotech (Rocky Hill, NJ, USA). All compounds
were dissolved in DMSO, except NAC, CTGF and VEGF,
which were solubilized in water.
Ethics statement
All procedures conformed to the Helsinki Declaration
for the research on humans. The experimental research
has been performed with the ethical approval provided
by the Ethics Committee of the Regional Hospital in
Cosenza, Italy.
Cell cultures
The SkBr3 breast cancer cells were maintained in RPMI-
1640 (Invitrogen, Milan, Italy) without phenol red, supple-
mented with 10% fetal bovine serum (FBS) and 100 μg/ml
penicillin/streptomycin. The murine cardiomyocyte-like
cell line HL-1 was kindly provided by Dr. William C.
Claycomb (Louisiana State University Medical Center,
New Orleans, LA, USA). In particular, the HL-1 cell line
was established from a mouse atrial cardiomyocyte tumor
excised from an adult female Jackson Laboratory-inbred
C57BLy6J mouse (Jackson Laboratory, Bar Harbor, Maine,
USA) [24]. HL-1 cells were cultured according to the
published protocol [24] in Claycomb medium (JRH Bios-
ciences, Sigma-Aldrich Srl, Milan, Italy) supplemented
with 10% FBS (JRH Bioscience, Sigma-Aldrich Srl), 100
μg/ml penicillin/streptomycin (Invitrogen, Milan, Italy),
0.1 mM norepinephrine (Sigma-Aldrich Srl) and 2 mM L-
glutamine (Invitrogen). Human umbilical vein endothelial
cells (HUVECs) were seeded on collagen-coated flasks
(Sigma-Aldrich Srl) and cultured in endothelial growth
medium (EGM) (Lonza, Milan, Italy), supplemented with
5% FBS (Lonza, Milan, Italy). All cell lines were grown in a
37°C incubator with 5% CO2. For hypoxic stimulation,
cells were treated with CoCl2 or cultured in the presence
of low oxygen tension (2% O2) in a HeraCell incubator
(ThermoScientific-Heraeus, Milan, Italy). Cells were
switched to medium without serum the day before
experiments.
Isolation, cultivation and characterization of CAFs
CAFs were extracted from six invasive mammary ductal
carcinomas obtained from mastectomies as previously
described [23]. Signed informed consent from all the
patients and IRB approval were obtained. In particular,
tissues obtained were cut into smaller pieces (1 to 2 mm
diameter), placed in digestion solution (400 IU collage-
nase, 100 IU hyaluronidase and 10% FBS, containing anti-
biotics and antimycotics solution) and incubated overnight
at 37°C. Cells were then separated by differential centrifu-
gation at 90 × g for two minutes. The supernatant
containing fibroblasts were centrifuged at 485 × g for eight
minutes, the pellet obtained was suspended in fibroblasts
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growth medium (Medium 199 and Ham’s F12 mixed 1:1
and supplemented with 10% FBS and 1% penicillin) and
cultured at 37°C, 5% CO2. In each patient, a second popu-
lation of fibroblasts was isolated from a noncancerous
breast tissue at least 2 cm from the outer tumor margin.
CAFs and fibroblasts were then expanded into two 15-cm
Petri dishes and stored as cells passaged for two to three
population doublings within a total 7 to 10 days after tis-
sue dissociation. We used CAFs and fibroblasts passaged
for up to five population doublings for subsequent experi-
ments to minimize clonal selection and culture stress,
which could occur during extended tissue culture. Primary
cells cultures of breast fibroblasts were characterized by
immunofluorescence. Briefly, cells were incubated with
human anti-vimentin (V9) and human anti-cytokeratin 14
(LL001), all antibodies were from Santa Cruz Biotechnol-
ogy, DBA (Milan, Italy). In order to assess fibroblast acti-
vation, we used anti-fibroblast activated protein a (FAPa)
antibody (H-56) purchased from Santa Cruz Biotechnol-
ogy, DBA (Milan, Italy) (data not shown). All experiments
were performed in each CAF population obtained from
six patients. Data presented were obtained in CAFs
derived from one patient; however, results similar to those
shown were found in CAFs derived from the other five
patients.
Gene reporter assays
The 2.6 kb VEGF promoter-luciferase construct contain-
ing full-length VEGF promoter sequence (22,361 to
+298 bp relative to the transcription start site) used in
luciferase assays was a kind gift from Dr. Pal Soumitro
(Harvard Medical School, Boston, MA, USA). CAFs or
SkBr3 cells (1 × 105) were plated into 24-well dishes
with 500 μL/well culture medium containing 10% FBS
and transfected for 24 h with control shRNA, shHIF-1a
or shGPER. Next, a mixture containing 0.5 μg of repor-
ter plasmid and 10 ng of pRL-TK was transfected within
cells. Transfections were performed using FuGENE 6
reagent as recommended by the manufacturer (Roche
Diagnostics, Milan, Italy). After 8 h, cells were treated
with 100 μM CoCl2 or exposed to low oxygen (2% O2)
for 12 h in serum-free medium. Luciferase activity was
measured with the Dual Luciferase Kit (Promega, Milan,
Italy) normalized to the internal transfection control
provided by Renilla luciferase activity. The normalized
relative light unit values obtained from cells treated with
vehicle were set as one-fold induction, from which the
activity induced by treatments was calculated.
Gene expression studies
Total RNA was extracted from cell cultures using
the Trizol commercial kit (Invitrogen) according to
the manufacturer’s protocol. RNA was quantified
spectrophotometrically and quality was checked by
electrophoresis through agarose gels stained with
ethidium bromide. Only samples that were not degraded
and showed clear 18S and 28S bands under ultraviolet
light were used for RT-PCR. Total cDNA was synthe-
sized from the RNA by reverse transcription using the
murine leukemia virus reverse transcriptase (Invitrogen)
following the protocol provided by the manufacturer.
The expression of selected genes was quantified by both
real-time RT-PCR using Step One® sequence detection
system (Applied Biosystems, Inc., Milan, Italy) and
semiquantitative RT-PCR [25]. Gene-specific primers
were designed using Primer Express version 2.0 software
(Applied Biosystems, Inc.) and are as follows: HIF-1a
Fwd: 5’-TGCATCTCCATCTTCTACCCAAGT-3’ and
Rev: 5’-CCGACTGTGAGTGCCACTGT-3’; GPER Fwd:
5’-ACACACCTGGGTGGACACAA-3’ and Rev: 5’-GGA-
GCCAGAAGCCACATCTG-3’; CTGF Fwd: 5’-ACC-
TGTGGGATGGGCATCT-3’ and Rev: 5’-CAGGCGGC
TCTGCTTCTCTA-3’; VEGF (human): Fwd: 5’- TGCA-
GATTATGCGGATCAAACC-3’ and Rev: 5’- TGCATT-
CACATTTGTTGTGCTGTAG-3’; VEGF (mouse) Fwd:
5’- GGAGATCCTTCGAGGAGCACTT-3’ and Rev:
5’- GGCGATTTA GCAGCAGATATAAGAA-3’; 18S
(human, mouse) Fwd: 5’-GGCGTCCCCCAACTTCTTA-
3’ and Rev: 5’- GGGCATCACAGACCTGTTATT -3. The
ribosomal protein 18S was used as a control gene to
obtain normalized values.
For semiquantitative PCR, primers were as follows:
HIF-1a Fwd: 5’- GCTGATTTGTGAACCCAT TC-3’
and Rev: 5’- CTGTACTGTCCTGTGGTGAC-3’; GPER
Fwd: 5’- CTGGGGAGTTTCCTG TCTGA -3’ and
Rev: 5’-GCTTGGGAAGTCACATCCAT-3’; CTGF Fwd:
5’-ATGGCATGAAGCCAGAGAGT-3’ and Rev: 3’-GG-
TCAGTGAGCACGCTAAAA-3’; VEGF (human) Fwd:
5’-GAGCTTCAGGACATTGCTGT-3’ and Rev: 5’-AG-
GAAGGTCAACCACTCACA-3’; VEGF (mouse) Fwd:
5’-CGTGTAAATGTTCCTGCAAA-3’ and Rev: 5’-CG-
TGTAAATGTTCCTGCAAA-3’; 36B4 (human) Fwd: 5’-
CTCAACATCTCCCCCTTCTC-3’ and Rev: 5’-CA-
AATCCCATATCCTCGTCC-3’; GAPDH (mouse) Fwd:
5’-ACCACAGTCCATGCCATCAC-3’ and Rev: 5’-TCC-
ACCACCCTGTTGCTGTA-3’. 36B4 and GAPDH were
used as control genes to obtain normalized values.
Western blot analysis
To prepare lysates, CAFs were washed in phosphate-
buffered saline (PBS) and solubilized with 50 mM Hepes
solution, pH 7.4, containing 1% (v/v) Triton X-100, 4
mM EDTA, 1 mM sodium fluoride, 0.1 mM sodium
orthovanadate, 2 mM phenylmethanesulfonyl fluoride
(PMSF), 10 μg/ml leupeptin and 10 μg/ml aprotinin.
Protein concentrations in the supernatant were deter-
mined according to the Bradford method. Cell lysates
(10 to 50 μg of protein) were electrophoresed through a
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reducing SDS/10% (w/v) polyacrylamide gel and electro-
blotted onto a nitrocellulose membrane. Membranes
were blocked and incubated with primary polyclonal
IgG antibody for HIF-1a (R&D Systems, Inc., Celbio,
Milan, Italy), GPER (N-15), CTGF (L-20), phosphory-
lated ERK1/2 (E-4), ERK2 (C-14), b-actin (C2), b-tubulin
(H-235-2) and appropriate secondary HRP-conjugated
antibodies, all purchased from Santa Cruz Biotechnology
(DBA). The levels of proteins and phosphoproteins were
detected with horseradish peroxidase-linked secondary
antibodies and revealed using the ECL® System (GE
Healthcare, Milan, Italy).
Gene silencing experiments
Cells were plated onto 10 cm dishes and transfected for 24
h before treatments with a control vector or an indepen-
dent shRNA sequence for each target gene using Fugene6
(Roche Diagnostics). The shRNA plasmid for HIF-1a and
the respective control plasmids were purchased from
SABioscience Corporation (Frederick, MD, USA). The
silencing of GPER expression was obtained by the con-
struct which we have previously described and used [26].
Immunofluorescence microscopy
Fifty percent confluent cultured CAFs, SkBr3 and HL-1
cells grown on coverslips were serum-deprived for 24 h
and treated for 12 h with 100 μM CoCl2 or exposed for
12 h to low oxygen tension (2% O2). Then cells were
fixed in 4% paraformaldehyde, permeabilized with 0.2%
Triton X-100, washed three times with PBS and incu-
bated overnight with a mouse primary antibody against
VEGF (C-1) (Santa Cruz Biotechnology, DBA). After
incubation, the slides were extensively washed with PBS
and incubated with 4′,6-Diamidino-2-phenylindole dihy-
drochloride (DAPI), (1:1,000), (Sigma-Aldrich Srl) and
donkey anti-mouse IgG-FITC (1:300; purchased from
Alexa Fluor, Invitrogen). For knockdown experiments,
cells were previously transfected for 24 h with shHIF-1a
or shGPER and respective negative control plasmids (as
described above) and then treated for 12 h with 100 μM
CoCl2, or cultured under hypoxia as indicated. Leica
AF6000 Advanced Fluorescence Imaging System sup-
ported by quantification and image processing software
Leica Application Suite Advanced Fluorescence (Leica
Microsystems CMS, GbH Mannheim, Germany) were
used for experiment evaluation.
Chromatin Immunoprecipitation (ChIP) assay
CAFs were grown in 10-cm dishes to 60 to 70% conflu-
ence, serum deprived for 24 h and then treated with
vehicle or 100 μM CoCl2 for 1 h. Thereafter, cells were
cross-linked with 1% formaldehyde and sonicated.
Supernatants were immuno-cleared with salmon DNA/
protein A-agarose (Upstate Biotechnology, Inc., Lake
Placid, NY, USA) and immunoprecipitated with anti-
HIF1a or anti-GPER antibody or nonspecific IgG. Pel-
lets were washed, eluted with a buffer consisting of 1%
SDS and 0.1 mol/L NaHCO3, and digested with protei-
nase K. DNA was obtained by phenol/chloroform
extractions and precipitated with ethanol. The yield of
target region DNA in each sample after ChIP was ana-
lyzed by real-time PCR. The primer for the -1,216 to
-883 region of the human VEGF promoter containing
the HRE site is 5’-CACAGACCTTCACAGCCATC-3’
(forward hHRE) and 5’-CCCAGCGTAGACAGTT-
GAGT-3’ (reverse hHRE). Data were normalized to the
input for the immunoprecipitation. For knockdown
experiments CAFs were previously transfected in serum-
free medium for 24 h with shHIF-1a or shGPER and
the respective control shRNA (as described above) and
then treated for 1 h with 100 μM CoCl2.
Migration assay
Migration assays were performed with CAFs in triplicate
using Boyden chambers (Costar Transwell, 8 mm polycar-
bonate membrane, Sigma Aldrich Srl). CAFs were trans-
fected with shRNA constructs directed against HIF-1a,
GPER or with an unrelated control shRNA construct in
regular growth medium. After 24 h, cells were exposed to
low oxygen tension (2% O2) or normoxia (20% O2) for 6 h
in medium without serum. Then, cells were maintained
for 24 h in normoxic conditions (20% O2) in medium
without serum. This experimental condition has been
designed in order to reproduce the unbalanced oxygena-
tion occurring within solid tumors, where the irregular
blood flow is responsible for hypoxia and reoxygenation
phases [27]. CAFs were, therefore, trypsinized and seeded
in the upper chambers. CTGF (100 ng/mL) was added to
the medium without serum in the bottom wells where
applicable. Six hours after seeding, cells on the bottom
side of the membrane were fixed and counted.
Conditioned medium
CAFs were cultured in regular growth medium to 80%
confluence. Then, cells were washed twice with PBS and
transfected in serum-free RPMI 1640 (Invitrogen) with
shHIF-1a, shGPER or control shRNA using Fugene 6
reagent as recommended by the manufacturer (Roche
Diagnostics) for 24 h. Subsequently, cells were incubated
under normoxic or hypoxic (2% O2) conditions for 12 h.
Thereafter, the culture supernatant was collected, centri-
fuged at 16,000 g for five minutes to remove cell debris
and used as conditioned medium in HUVECs.
Protein precipitation with Trichloroacetic acid (TCA)
Conditioned medium from CAFs (see above) was col-
lected, centrifuged at 16,000 g for five minutes to remove
cell debris and 10 μg/mL BSA (final concentration) was
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added as a control for precipitation efficiency. TCA (100%
solution) was added to a final concentration of 20% to
conditioned media. After a 20-minute incubation on ice,
the samples were centrifuged at 31,000 g for 20 minutes
(4°C). Pellets were washed with cold acetone, centrifuged
at 31,000 g for 30 minutes (4°C), air dried and resus-
pended in protein lysis buffer (described above). Protein
concentrations were estimated using the Bradford Method
and immunoblot analysis was performed as described
above, using 100 μg protein/lane.
Tube formation assay
The day before the experiment, confluent HUVECs were
starved overnight at 37°C in serum free medium (EBM,
Lonza, Milan, Italy). Growth factor-reduced Matrigel®
(Cultrex, Trevigen, Inc., Helgerman Court, Gaithersburg,
USA) was thawed overnight at 4°C on ice, plated on the
bottom of pre-chilled 96-well plates and left at 37°C for
1 h for gelification. Starved HUVECs were collected by
enzymatic detachment (0.25% trypsin-EDTA solution,
Invitrogen), counted and resuspended in conditioned
medium from CAFs. Then, 10,000 cells/well were
seeded on Matrigel® and incubated at 37°C. Tube for-
mation was observed starting from 2 h after cell seeding
and quantified by using the software NIH ImageJ
(National Institutes of Health (NIH), Rockville Pike,
Bethesda, Maryland, USA).
Statistical analysis
Statistical analysis was performed using ANOVA followed
by Newman-Keuls’ testing to determine differences in
means. P < 0.05 was considered as statistically significant.
Results
Hypoxia induces HIF-1a and GPER expression in CAFs
In order to provide further insight into the response to
hypoxia in main components of the tumor microenviron-
ment like CAFs, we began our study showing that hypoxia
induces the mRNA expression of both HIF-1a and its tar-
get gene GPER, as ascertained by real time PCR (Figure 1)
and semi-quantitative PCR (data not shown). In particular,
CAFs were treated from 1 h to 24 h with the hypoxia
mimetic agent CoCl2 (100 μM) (Figure 1a) or cultured in
the presence of low oxygen tension (2% O2) (Figure 1b).
The induction of HIF-1a and GPER mRNA expression
was paralleled by increased protein levels of these factors
in CAFs treated from 1 h to 24 h with 100 μM CoCl2
(Figure 1c) or exposed to a low oxygen tension (2% O2)
(Figure 1d). Next, silencing HIF-1a expression, the induc-
tion of GPER by CoCl2 was abrogated (Figure 1e,
Additional file 1a), indicating that HIF-1a is required for
the transcription of GPER in CAFs exposed to hypoxic
conditions. In order to assess the transduction signaling
involved in the aforementioned responses, we determined
the rapid ERK1/2 phosphorylation (from 15 minutes up to
60 minutes) following the treatment with 100 μM CoCl2
(Figure 2a). Accordingly, we observed similar effects on
ERK1/2 activation culturing CAFs in the presence of low
oxygen tension (2% O2 for 30 minutes) (Figure 2b). Next,
the treatment with 100 μM CoCl2 for 30 minutes in the
presence of 300 μM of the ROS scavenger NAC did not
induce the ERK1/2 phosphorylation (Figure 2c). Moreover,
the increase of HIF-1a and GPER observed treating CAFs
for 3 h with 100 μM CoCl2 was no longer evident in the
presence of 300 μM NAC and 10 μM of the MEK inhibi-
tor PD (Figure 2d). On the basis of these results, it could
be argued that hypoxia-induced ROS may trigger the
ERK1/2 phosphorylation, which is involved in the up-reg-
ulation of both HIF-1a and GPER expression.
HIF-1a and GPER are involved in the expression of VEGF
induced by hypoxia
Considering the ability of a low oxygen environment to
trigger the production of pro-angiogenic factors in solid
tumors, we aimed to evaluate whether hypoxia may
promote the expression of an important HIF-1a target
gene like VEGF. As shown in Figure 3a, the treatment
with CoCl2 induced the mRNA expression of VEGF in a
time-dependent manner in both CAFs and SkBr3 breast
cancer cells. Similar results were obtained in a completely
different model system, such as HL-1 cardiomyocytes
(Additional file 2). Next, CoCl2 and a low oxygen tension
(2% O2) activated a VEGF promoter reporter gene which
was transfected in CAFs and SkBr3 cells (Figure 3b, c).
Notably, the aforementioned transcriptional response to
hypoxia was abrogated knocking-down HIF-1a and GPER
expression (Figure 3d, e and Additional file 1c, d). CoCl2
and a low oxygen tension (2% O2) promoted also VEGF
protein expression in CAFs, as evidenced by immunofluor-
escence experiments (Figure 4). The induction of VEGF
protein levels was abolished, silencing HIF-1a and GPER
expression (Figure 5 and Additional file 1a, b), further
highlighting their involvement in the regulation of VEGF
by hypoxia. Analogously, the up-regulation of VEGF
protein expression upon exposure to hypoxia in SkBr3
(Figure 6a) and HL-1 cells (Figure 7a) was no longer evi-
dent, knocking down the expression of GPER (Figures 6b
and 7b and Additional file 1e) and HIF-1 a (data not
shown). Taken together, these results suggest that HIF-1a
and GPER are involved in the regulation of VEGF
expression induced by hypoxia.
HIF-1a and GPER are both recruited to the VEGF
promoter and involved in VEGF-mediated tube formation
induced by hypoxia
As HIF-1a and GPER are required for the hypoxia-
induced VEGF expression, we next determined by ChIP
assay that HIF-1a (Figure 8a) and GPER (Figure 8b) are
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Figure 1 Hypoxia induces the expression of HIF-1a and GPER in CAFs. (a-d) The exposure to 100 μM CoCl2 (a, c) or low oxygen tension
(2% O2 for 3 h) (b, d) up-regulate the mRNA (a, b) and protein (c, d) expression of HIF-1a and GPER as evaluated by real-time PCR and
immunoblotting, respectively. In RNA experiments, values are normalized to the 18S expression and shown as fold changes of mRNA expression
induced by CoCl2 compared to cells treated with vehicle. (e) The up-regulation of GPER observed treating CAFs for 6 h with 100 μM CoCl2 is
abrogated by silencing HIF-1a. Each data point represents the mean ± SD of three independent experiments. Side panel shows densitometric
analysis of the blots normalized to b-actin. (○), (●) P < 0.05 for cells receiving vehicle (-) or cells cultured under normoxia versus CoCl2 treatment
or cells cultured under hypoxia.
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both recruited to the HRE site located within the VEGF
promoter sequence in CAFs exposed to CoCl2 for 1 h.
Interestingly, GPER was required for the recruitment of
HIF-1a to the promoter of VEGF, as evidenced knock-
ing-down the expression of GPER (Figure 8c). In paral-
lel, the silencing of HIF-1a abolished the recruitment of
GPER to the HRE site within the VEGF promoter
sequence (Figure 8d). Altogether, these findings suggest
that a functional interplay between HIF-1a and GPER
leads to the hypoxia-induced transcription of VEGF.
On the basis of these data, we then examined whether
conditioned medium from hypoxia-stimulated CAFs could
promote in HUVECs the formation of tubule-like struc-
tures that represent a useful model system for the evalua-
tion of the neoangiogenesis process [28]. In particular,
HUVECs were cultured on GFR-Matrigel®-coated plates
which prevent the formation of capillary-like structures, as
previously reported [29]. Notably, HUVECs cultured in
normoxic medium from CAFs did not assemble into cord-
like structures, while HUVECs grown in medium from
CAFs maintained in hypoxic conditions (2% O2 for 12 h)
displayed a complex ramified network of tubules (Figure
9a). Moreover, in HUVECs cultured with hypoxic medium
(2% O2 for 12 h) collected from CAFs, which were pre-
viously transfected with a shHIF-1a or shGPER, tube
formation was no longer observed (Figure 9b, c). The
addition of 10 ng/mL VEGF to the hypoxic medium from
GPER-silenced CAFs restored the ability to form tubule
structures in HUVECs (Figure 9c). The aforementioned
findings were quantified and recapitulated in Additional
file 3. Next, we determined that the up-regulation of
VEGF protein levels in hypoxic medium from CAFs is no
longer evident, knocking down HIF-1a and GPER expres-
sion (Additional file 4). Hence, these results clearly suggest
that VEGF may be considered as a target of the HIF-1a/
GPER transduction signaling.
HIF-1a and GPER are involved in hypoxia-induced
expression of CTGF and migration of CAFs
In order to further corroborate the stimulatory role
exerted by HIF-1a/GPER signaling in hypoxic conditions,
we turned to a different model system. CoCl2 and low
oxygen tension (2% O2) induced CTGF up-regulation at
both mRNA (Figure 10a) and protein level (Figure 10b, c)
in CAFs. Silencing HIF-1a as well as knocking down
GPER expression, the up-regulation of CTGF upon CoCl2
was abolished (Figure 10d, e). As a biological counterpart,
the migration of CAFs cultured under low oxygen tension
(2% O2) was prevented, silencing HIF-1a and GPER
expression and rescued, adding CTGF (Figure 10f).
Figure 2 Hypoxia stimulates the expression of HIF-1a and GPER through ERK1/2 activation in CAFs. The treatment with 100 μM CoCl2 (a)
or the exposure to low oxygen tension (2% O2 for 30 minutes) (b) induce ERK1/2 phosphorylation, which is prevented by using 300 μM of the
free radical scavenger NAC (c). (d) Immunoblots of HIF-1a and GPER from CAFs treated for 3 h with vehicle (-) or 100 μM CoCl2 alone and in
combination with 300 μM NAC or 10 μM ERK1/2 inhibitor PD. Results shown are representative of three independent experiments. Side panels
show densitometric analysis of the blots normalized to ERK/2 or b-actin. (○), (●) P < 0.05 for cells receiving vehicle (-) or cultured under
normoxia vs cells treated with CoCl2 or cells cultured under hypoxia.
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Figure 3 HIF-1a and GPER are involved in the hypoxia-induced transcriptional activation of VEGF. (a) The mRNA expression of VEGF is
up-regulated in CAFs and SkBr3 cells treated with 100 μM CoCl2, as evaluated by real-time PCR. Values are normalized to the 18S expression and
shown as fold changes of mRNA expression induced by CoCl2 compared to cells treated with vehicle (-). Columns, mean of three independent
experiments; bars, SD. (b) The VEGF promoter plasmid (pVEGF) is transactivated in CAFs and SkBr3 cells treated with 100 μM CoCl2 for 12 h (b)
or exposed to low oxygen tension (2% O2) for 12 h (c). The transactivation of the VEGF promoter observed in SkBr3 cells treated for 12 h with
100 μM CoCl2 is abrogated by silencing HIF-1a (d) or GPER expression (e). The luciferase activities were normalized to the internal transfection
control and values of cells receiving vehicle or cultured under normoxia were set as one-fold induction upon which the activities induced by
CoCl2 treatment or hypoxia were calculated. Each data point represents the mean ± SD of three independent experiments performed in
triplicate. (○), (●) P < 0.05 for cells receiving vehicle (-) or cultured under normoxia vs cells treated with CoCl2 or cells cultured under hypoxia.
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Collectively, our data may suggest that HIF-1a/GPER
signaling mediates different biological outcomes in CAFs
exposed to hypoxia.
Discussion
In the present study, we provide novel evidence regarding
the regulation of VEGF, which plays a fundamental role in
mediating hypoxia-induced tumor angiogenesis [30,31]. In
particular, our results demonstrate that a low oxygen ten-
sion stimulates through the ERK1/2 transduction pathway
the HIF-1a dependent expression of GPER, which contri-
butes to the regulation of VEGF in both CAFs and breast
cancer cells. Moreover, we show that following hypoxic
conditions, HIF-1a and GPER are both recruited to the
HRE site located within the VEGF promoter region and
cooperatively act as a functional complex for the transcrip-
tion of VEGF. As a biological counterpart, we evidence
that HIF-1a and GPER mediate endothelial tube forma-
tion in HUVECs cultured in medium from CAFs which
were previously exposed to hypoxia. Further corroborating
these findings, we demonstrate that the cross-talk between
HIF-1a and GPER regulates the expression of the migra-
tory factor CTGF, which has been acknowledged as a tar-
get gene of both HIF-1a and GPER [19,20].
Figure 4 Hypoxia induces VEGF protein expression in CAFs. Evaluation of VEGF expression by immunofluorescence assays. CAFs were
treated for 12 h with vehicle (a2) or 100 μM CoCl2 (a3), or cultured under normoxia (b2) or low oxygen tension (2% O2 for 12 h) (b3), as
indicated. VEGF accumulation is evidenced by the green signal. Nuclei were stained by DAPI (blue signal) (a1, b1). For descriptive purposes, each
side panel shows the plot profiles obtained at the level of the yellow line of the corresponding inset using the program WCIF Image J for
Windows. Note the higher values indicating zones of intense labeling. Images shown are representative of 20 random fields of three
independent experiments.
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Figure 5 HIF-1a and GPER mediate the hypoxia-induced expression of VEGF in CAFs . Evaluation of VEGF expression by
immunofluorescent microscopy in CAFs transfected for 24 h with control shRNA (a2, a3, b2, b3), shHIF-1a (a4, a5) or shGPER (b4, b5). Cells were
treated with vehicle or 100 μM CoCl2 for 12 h, as indicated and VEGF accumulation is evidenced by the green signal. Nuclei were stained by
DAPI (blue signal) (a1, b1). For descriptive purposes, each side panel shows the plot profiles obtained at the level of the yellow line of the
corresponding inset using the program WCIF Image J for Windows. Note the higher values indicating zones of intense labeling. Images shown
are representative of 20 random fields of three independent experiments.
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HIF-1 is a master regulator of cellular adaptation to
oxygen deprivation and acts as a survival factor in
hypoxic tumor environment, mainly activating the tran-
scription of genes involved in glycolytic metabolism,
oxygen consumption, cell migration and invasion
[15,32]. Besides, hypoxia stimulates through HIF-1 the
expression of anti-apoptotic, proliferative and angiogenic
factors that drastically change the biological properties
Figure 6 GPER is involved in VEGF expression by hypoxia in SkBr3 breast cancer cells. (a) SkBr3 cells were treated for 12 h with vehicle
(a2) or 100 μM CoCl2 (a3), as indicated. VEGF accumulation is evidenced by the green signal. (b) SkBr3 cells were transfected for 24 h with
control shRNA (b2, b3) or shGPER (b4, b5) and treated with vehicle (b2, b4) or 100 μM CoCl2 (b3, b5) for 12 h, as indicated. VEGF accumulation
was evidenced by the green signal. Nuclei were stained by DAPI (blue signal) (a1, b1). For descriptive purposes, each side panel shows the plot
profiles obtained at the level of the yellow line of the corresponding inset using the program WCIF Image J for Windows. Note the higher
values indicating zones of intense labeling. Images shown are representative of 20 random fields of three independent experiments.
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of tumor cells towards malignant features [12]. In this
context, we have recently demonstrated that GPER may
be included among the HIF-1 target genes as the up-
regulation of GPER induced by hypoxia occurs through
the recruitment of HIF-1a to the HRE site located
within the GPER promoter sequence in breast cancer
cells and cardiomyocytes [19]. In particular, GPER-
mediated the antiapoptotic effects exerted by estrogens
Figure 7 GPER is involved in VEGF expression by hypoxia in HL-1 murine cardiomyocytes. (a) HL-1 cells were treated for 12 h with
vehicle (a2) or 100 μM CoCl2 (a3), as indicated. VEGF accumulation is evidenced by the green signal. (b) HL-1 cells were transfected for 24 h
with control shRNA (b2, b3) or shGPER (b4, b5) and treated with vehicle (b2, b4) or 100 μM CoCl2 (b3, b5) for 12 h, as indicated. VEGF
accumulation is evidenced by the green signal. Nuclei were stained by DAPI (blue signal) (a1, b1). For descriptive purposes, each side panel
shows the plot profiles obtained at the level of the yellow line of the corresponding inset using the program WCIF Image J for Windows. Note
the higher values indicating zones of intense labeling. Images shown are representative of 20 random fields of three independent experiments.
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in hypoxic conditions, suggesting that this receptor may
contribute to the adaptation of cancer cells to a low
oxygen environment [19].
GPER may be considered as a predictor of cancer malig-
nancy and aggressiveness considering that its expression
has been associated with negative clinical features and
poor survival rates in diverse types of tumors [33-35].
Therefore, huge efforts are currently underway to unravel
the mechanisms that rule its regulation and function.
Indeed, the development and characterization of drugs
that target key players of cancer progression like GPCRs
[36,37], and particularly GPER, are currently innovative
topics under investigation [38,39].
In this context, estrogenic GPER signaling has been
shown to trigger relevant biological effects like prolifera-
tion and migration in diverse cancer cells and in CAFs
derived from breast tumors [40-43]. Notably, GPER
exhibited the peculiar property to act in CAFs as a
transcriptional regulator together with the epidermal
growth factor receptor (EGFR), hence leading to the
up-regulation of Cyclin D, which has been largely involved
in cell proliferation [23]. Increasing evidence has suggested
that CAFs may drive cancer phenotype mainly through a
paracrine action exerted by the production of various
growth factors and chemokines secreted in the tumor
microenvironment [3,4,44,45]. Indeed, the stromal contri-
bution to the development of a wide variety of tumors has
been supported by animal models of cancer pathogenesis
[46,47] and extensive clinical studies [48]. In this vein, it
has been shown that malignant cells recruit into the
tumor mass diverse stromal components like CAFs,
inflammatory and vascular cells that actively cooperate
towards cancer progression [46,49-51]. In particular, CAFs
elicit in breast carcinomas relevant biological activities,
Figure 8 HIF-1a and GPER are recruited to the VEGF promoter sequence. CAFs treated for 1 h with 100 μM CoCl2 were submitted to the
chromatin immunoprecipitation procedure using anti-HIF-1a (a) or anti-GPER (b) antibodies. For knockdown experiments, CAFs were transfected with
control shRNA and shGPER (c) or with control shRNA and shHIF-1a (d), treated for 1 h with 100 μM CoCl2 and then submitted to the chromatin
immunoprecipitation procedure using anti-HIF-1a (c) or anti-GPER (d) antibodies. The amplified sequences were evaluated by real-time PCR. Each data
point represents the mean ± SD of three independent experiments. (○) P < 0.05 for cells receiving vehicle vs CoCl2 treatment.
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including the stimulation of new blood vessels formation,
which closely correlates with cancer growth, metastasis
and poor prognosis [52,53]. In this context, our present
data add a further mechanism through which the tumor
microenvironment may promote angiogenesis, as the HIF-
1a/GPER signaling was shown to mediate the up-regula-
tion of VEGF expression in CAFs cultured in hypoxic
conditions. Considering that VEGF is one of the most
important factors mediating the complex process of angio-
genesis [54], its action has been widely involved in the
development of many types of tumors, including breast
cancer [55]. Accordingly, it has been shown that the
ectopic expression of VEGF in MCF-7 breast cancer cells
may promote tumor growth in vivo [56], whereas the
blockade of VEGF has been associated with the growth
arrest of breast carcinomas in nude mice [57,58]. Thus,
given the crucial role exerted by VEGF in tumor develop-
ment and prognosis, a great deal of interest is currently
addressed to a better understanding of its regulation and
function. In this regard, VEGF was shown to be regulated
by hypoxia mainly through HIF-1a, which may interact
with numerous factors to boost VEGF expression [59,60].
Further extending the current knowledge on the complex
regulation of VEGF, our data suggest that GPER may
contribute to the HIF-1a mediated transcriptional
responses in hypoxic tumor microenvironment towards
new blood vessel formation. Notably, an increased VEGF
production was recently shown to parallel an elevated
GPER expression in endometrial cancer patients with low
survival rates [61]. These data in combination with our
Figure 9 Involvement of HIF-1a and GPER in hypoxia-induced tube formation. Tube formation was evaluated in HUVECs cultured for 2 h
in medium collected from CAFs which were cultured under normoxia or hypoxia (2% O2 for 12 h). To this end, CAFs were transfected with
control shRNA (a), shHIF-1a (b) or shGPER (c) and exposed to hypoxia, as indicated. Tube formation is rescued in HUVECs treated with 10 ng/mL
VEGF and cultured in medium from CAFs transfected with shGPER and cultured under hypoxia (2% O2 for 12 h). Data are representative of three
independent experiments performed in triplicate.
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findings may suggest that in estrogen-dependent cancer
cells diverse molecular mechanisms could converge on the
production of cytokines and growth factors, promoting an
enhancement of malignant epithelial growth and invasion
through autocrine and/or paracrine pathways. Interest-
ingly, we have determined that the up-regulation of VEGF
relied on HIF-1a/GPER signaling also in HL-1 cardiomyo-
cytes exposed to hypoxia, suggesting that this transduction
Figure 10 Involvement of HIF-1a and GPER in hypoxia-induced expression of CTGF and migration of CAFs. (a) The mRNA expression of CTGF
is induced after the stimulation of CAFs with 100 μM CoCl2, as indicated. Values are normalized to the 18S expression and shown as fold changes of
mRNA expression induced by CoCl2 compared to cells treated with vehicle. The protein expression of CTGF is induced by 100 μM CoCl2 (b) or
low oxygen tension (2% O2, for 4 h) (c). The up-regulation of CTGF protein expression observed upon 100 μM CoCl2 treatment is abrogated silencing
HIF-1a (d) or GPER (e) expression. The migration of CAFs induced by hypoxia (2% O2, for 6 h) is prevented knocking down HIF-1a and GPER
expression. Cell migration is rescued in CAFs transfected with shGPER, exposed to hypoxia (2% O2, for 6 h) and treated with 100 ng/ml CTGF (f).
Results shown are representative of three independent experiments. Side panels show densitometric analysis of the blots normalized to b-actin. (○) P
< 0.05 for cells receiving vehicle (-) or cells cultured under normoxia versus CoCl2 treatment or cells cultured under hypoxia.
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mechanism may be implicated in additional pathophysio-
logical conditions, such as the hypoxic myocardium. In
this regard, it should be mentioned that recent studies
have suggested a cardioprotective role exerted by GPER in
stressful conditions following hypoxia [62]. These data in
combination with the results obtained in the present study
may indicate that GPER could elicit cardiotropic effects
also through its ability to regulate the expression of VEGF,
which mainly contributes to adaptive responses following
myocardial ischemic injury [63].
As it concerns the signaling cascades activated by
hypoxia, we here demonstrate that the ROS-mediated
ERK1/2 activation is involved in the up-regulation of HIF-
1a and GPER expression upon low oxygen tension. In this
regard, it should be mentioned that ROS play a relevant
role in the biological responses to re-oxygenation; how-
ever, decreased oxygen levels may be sufficient to trigger
HIF-1-dependent gene expression through the ROS
production [64-66]. In addition, the rapid responses to
hypoxia are mediated by multiple transduction pathways
activated also upon GPER stimulation [67,68]. Further stu-
dies are needed to better clarify the functional cross-talk
between HIF-1a and GPER, particularly following both
hypoxic and estrogenic stimulations. For instance, estro-
gens regulate HIF-1a expression and function in a stress-
ful environment [20], indicating an intricate cooperation
between these two main factors mainly involved in tumor
progression. Interestingly, in the current investigation, the
biological interaction between HIF-1a and GPER upon
hypoxic conditions was corroborated by the up-regulation
of an important migratory stimulator and GPER target
gene like CTGF. Accordingly, the migration of CAFs
induced by hypoxia was abolished, silencing HIF-1a and
GPER expression, hence confirming their contribution to
this relevant cell response.
The results obtained in the current study may also
disclose a unique ligand-independent action elicited by
GPER. This issue could be a further attractive topic
which remains to be elucidated in future studies.
Altogether, our findings recapitulate in CAFs exposed
to hypoxia the engagement of the HIF-1a/GPER signal-
ing towards the regulation of pivotal genes involved in
angiogenic and metastatic processes. Anyway, further
studies are required to better define the role exerted by
this transduction pathway in diverse pathophysiological
conditions as well as the molecular mechanisms driving
the biological responses to hypoxia through the func-
tional interaction between HIF-1a and GPER.
Conclusions
Within the tumor microenvironment exposed to hypoxia,
CAFs have been involved in the generation of new blood
vessels which mainly support cancer progression. Our
current data highlight the stimulatory role exerted by the
HIF-1a/GPER signaling in the multistep process of tumor
neoangiogenesis fostered by CAFs. Considering the crucial
interplay between cancer cells and stroma, the HIF-1a/
GPER transduction pathway may be pointed out as a
further biological target towards innovative treatments in
breast cancer.
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